Erustes Adolfo G, Abílio Vanessa C, Bincoletto Claudia, Piacentini Mauro, Pereira Gustavo J S, Smaili Soraya S
Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil.
Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil; National Institute for Translational Medicine (INCT-TM), National Council for Scientific and Technological Development (CNPq/CAPES/FAPESP), Ribeirão Preto, Brazil.
Brain Res. 2025 Mar 1;1850:149414. doi: 10.1016/j.brainres.2024.149414. Epub 2024 Dec 20.
Numerous studies have explored the role of cannabinoids in neurological conditions, chronic pain and neurodegenerative diseases. Restoring autophagy has been proposed as a potential target for the treatment of neurodegenerative diseases. In our study, we used a neuroblastoma cell line that overexpresses wild-type α-synuclein to investigate the effects of cannabidiol on autophagy modulation and reduction in the level of cytosolic α-synuclein. Our results demonstrated that cannabidiol enhances the accumulation of LC3-II- and GFP-LC3-positive vesicles, which indicates an increase in autophagic flux. In addition, cannabidiol-treated cells showed a reduction in cytosolic α-synuclein levels. These effects were inhibited when the cells were treated with a CB receptor-selective antagonist, which indicates that the biological effects of cannabidiol are mediated via its interaction with CB receptor. Additionally, we also observed that cannabinoid compounds induce autophagy and α-synuclein degradation after they interact with the CB receptor. In summary, our data suggest that cannabidiol induces autophagy and reduces cytosolic α-synuclein levels. These biological effects are mediated preferentially through the interaction of cannabidiol with CB receptors, and therefore, cannabinoid compounds that act selectively on this receptor could represent a new approach for autophagy modulation and degradation of protein aggregates.
众多研究探讨了大麻素在神经疾病、慢性疼痛和神经退行性疾病中的作用。恢复自噬已被提出作为治疗神经退行性疾病的一个潜在靶点。在我们的研究中,我们使用了一种过表达野生型α-突触核蛋白的神经母细胞瘤细胞系,来研究大麻二酚对自噬调节以及胞质α-突触核蛋白水平降低的影响。我们的结果表明,大麻二酚增强了LC3-II和GFP-LC3阳性囊泡的积累,这表明自噬通量增加。此外,经大麻二酚处理的细胞显示胞质α-突触核蛋白水平降低。当细胞用CB受体选择性拮抗剂处理时,这些效应受到抑制,这表明大麻二酚的生物学效应是通过其与CB受体的相互作用介导的。此外,我们还观察到大麻素化合物在与CB受体相互作用后诱导自噬和α-突触核蛋白降解。总之,我们的数据表明大麻二酚诱导自噬并降低胞质α-突触核蛋白水平。这些生物学效应主要通过大麻二酚与CB受体的相互作用介导,因此,选择性作用于该受体的大麻素化合物可能代表一种自噬调节和蛋白质聚集体降解的新方法。